Avivagen Announces Appointment of James Nickerson as President

Ottawa, ON /Business Wire/ January 25, 2022 /– Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is excited to announce the appointment of James  (“Jamie”) Nickerson, PhD as President of Avivagen. The appointment will be effective immediately.

“Jamie has been one of the most important members of Avivagen since the early days of the organization. His impressive track record contributing to both the science behind our offerings, as well as the growth of the business surrounding them, makes him the perfect individual to lead the next phase of growth for our company,” says Kym Anthony, Chief Executive Officer of Avivagen. “I look forward to working closely with Jamie as he establishes himself in the role and assumes leadership of Avivagen during this exciting and important stage of the company’s success.”

Currently Mr. Nickerson holds the role of Vice President of Business Development and Innovation for Avivagen. In this role he has been crucial in identifying and establishing a number of the strategic and  important customer and distribution partner relationships that are core to Avivagen’s ongoing growth and global expansion. He has also been central in finding new applications for the company’s OxC-beta™  product in both the animal and human nutrition fields.

Upon joining Avivagen in 2007, Mr. Nickerson established Avivagen’s Charlottetown biological research facility and directed the research and development program as senior research biologist. Over the next 15 years he held progressively senior roles within the company, including Director of Biology and Director of Commercialization Science, prior to taking over Business Development and Innovation responsibilities. During this period he also co-authored six scientific papers on Avivagen’s oxidized carotenoid technology platform, and is listed as an author on seven patents relating to the company’s product.

“I’ve been proud to be a part of the Avivagen journey for the past 15 years and am very excited to have the opportunity to lead this exciting next phase of the company,” said Mr. Nickerson. “We have laid the foundation to become an important global player in the future of both animal and human nutrition at a time when antibiotic effectiveness is waning in both areas. There is a bright future ahead for Avivagen, and I look forward to working closely with our team, our customers, our partners and our shareholders to take full advantage of the opportunities at hand.”

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance.  It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions.

Statements set out in this news release relating to the future growth and prospects for Avivagen and the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen’s control.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com
Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.

230 Responses

  4. Hello! Do you know if they make any plugins to assist with SEO?

    I’m trying to get my blog to rank for some targeted keywords but
    I’m not seeing very good gains. If you know of any
    please share. Thanks!

  5. I am extremely impressed with your writing skills and also
    with the layout on your blog. Is this a paid
    theme or did you modify it yourself? Either
    way keep up the nice quality writing, it’s rare to
    see a nice blog like this one today.

  6. Hey there, You’ve done a fantastic job. I will definitely digg it and personally
    recommend to my friends. I’m sure they will be benefited from this web site.

  7. Great items from you, man. I have take into account your stuff previous to and
    you are simply extremely fantastic. I actually like
    what you’ve bought here, really like what you are saying and the best way in which you assert it.
    You make it entertaining and you still care for to keep it wise.
    I cant wait to learn much more from you. This is really a tremendous site.

  8. Hello, I think your blog might be having browser compatibility issues.
    When I look at your website in Firefox, it looks fine but when opening in Internet Explorer, it has some overlapping.

    I just wanted to give you a quick heads up!
    Other then that, great blog!

  27. Im excited to discover this web site. I need to to thank you for ones time for this wonderful read!! I definitely savored every bit of it and I have you bookmarked to look at new information in your web site.

  31. Normally I don’t read article on blogs, however I wish to say
    that this write-up very forced me to take a look at and do so!

    Your writing taste has been amazed me. Thanks,
    very great post.

  87. I think everything composed was actually very reasonable.
    But, what about this? suppose you were to write a killer title?

    I mean, I don’t want to tell you how to run your
    blog, but suppose you added a headline to possibly get people’s attention? I mean Avivagen Announces Appointment of James Nickerson as President – Avivagen is a
    little vanilla. You ought to glance at Yahoo’s home page
    and see how they write post titles to grab people to open the links.
    You might try adding a video or a related pic or two to get people excited
    about what you’ve got to say. Just my opinion, it might bring your website a
    little bit more interesting.

  137. I will immediately clutch your rss as I can not find your e-mail subscription link or e-newsletter service.
    Do you have any? Please let me recognise
    in order that I could subscribe. Thanks.

  139. My spouse and I absolutely love your blog and find many of your post’s to be precisely
    what I’m looking for. Do you offer guest writers to write content to suit your needs?
    I wouldn’t mind publishing a post or elaborating on a lot of the subjects you write in relation to here.

    Again, awesome weblog!

  179. Hey would you mind stating which blog platform you’re using?
    I’m planning to start my own blog in the near future but
    I’m having a hard time deciding between BlogEngine/Wordpress/B2evolution and Drupal.
    The reason I ask is because your layout seems
    different then most blogs and I’m looking for something unique.

    P.S Sorry for getting off-topic but I had to ask!

  228. SterJo Wireless Passwords Review

    SterJo Wireless Passwords, finally, has a version for Windows! For those who still have the 7-year old PC and remember the days when WLAN was just a fun thing in which you read a couple of magazines while the laptop internet-loaded and checked your emails; you might wanna transfer those windows memories onto your Windows 8.1 PC as SterJo Wireless Passwords is now available for the PC platform at the same time that https://xn—-8sbkdqibmrdgt3a.xn--p1ai/bitrix/redirect.php?goto=https://ulabartool.weebly.com

    6add127376 yelicar

  229. KekuMate is a MIDI/AU Controller plugin which will let you program at MIDI events. It has a barebone user interface to let you easily map and control your virtual instruments and DAWs. It is designed based on simplicity. Quickly map any key on your keyboard that is of importance for you. Create and destroy controllers or third party controllers quickly by hand. KekuMate triggers control curves that have been designed to be easy to understand and work smoothly together https://rasstemkarnnit.weebly.com

    6add127376 payacha

  230. Accessories
    To produce the high-quality CAD models needed, SLS was used for 3D printing, and the RoboticPro Robotic Tool Controller took care of duplicating the final product onto as many models as needed, producing a customized learning experience for each individual user.

    Epicenter

    It is developed and published by Epicenter Technologies, the company behind the HoloAnatomy visualization platform.

    References

    External links

    HoloAnatomy https://upaltete.weebly.com

    6add127376 religaul

Leave a Reply

Your email address will not be published.